G
GRO Biosciences
Transforms protein therapeutics with new amino acid building blocks to treat incurable diseases
About GRO Biosciences
GRO Biosciences operates at the intersection of computational protein design and synthetic biology to create advanced protein therapeutics. The company has engineered multiple genomically recoded strains of bacteria capable of incorporating non-standard amino acids into proteins. This innovation results in therapeutics with increased potency, stability, and targeted delivery. GRO Biosciences primarily focuses on developing improved protein therapeutics for conditions such as diabetes and growth disorders. The company serves the biopharmaceutical market, targeting healthcare providers and patients in need of next-generation treatments. Its business model revolves around leveraging its proprietary technology platform to develop and commercialize these therapeutics, generating revenue through product sales and potential partnerships. Keywords: computational protein design, synthetic biology, protein therapeutics, genomically recoded bacteria, non-standard amino acids, increased potency, stability, targeted delivery, diabetes treatment, growth disorders.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2016
- Headquarters
- Boston, United States
- Employees
- 1
- Open positions
- None listed
- Dealroom signal
- 59.5/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Diabetes, Biotechnology, Synthetic Biology, Spinout, Alternative Protein, Macro-Nutrients, Biotech and Pharma, proteomics, DT and LS, science-based
Latest news
Press, funding announcements and product moves mentioning GRO Biosciences.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Jul 2024 | $60M | $241M | Innovation Endeavors · Digitalis Ventures · Atlas Venture · Redmile Group | ↗ |
| SERIES AOther financing | Nov 2021 | $25M | $100M | Innovation Endeavors · Leaps by Bayer · Digitalis Ventures · Redmile Group | — |
Growth signals
Latest recorded traffic for GRO Biosciences is 700 monthly website visits, down 6.7% over the last three months. GRO Biosciences's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed7 investors entered at this stage
Digitalis Ventures
Heritage Provider Network
OS Fund
Pillar VC
Innovation Endeavors
Wilson Sonsini
US National Science Foundation
Series A4 investors entered at this stage
Leaps by Bayer
Redmile Group
Atlas Venture
Access Biotechnology
Other known investors1 additional known investor
Harvard University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about GRO Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See GRO Biosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.